GlassScriptPhysician profile
Stacy Lahti
NPI 1386694552
$4,361.78
in general payments reported to CMS, 2019-2025
30 companies · $572 in 2025
The $572 reported for 2025 was more than what 78% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $505 · 2021: $563 · 2022: $1,477 · 2023: $184 · 2024: $437 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,458.63 | 2019-2024 | |
| Abbvie INC. | $685.34 | 2019-2025 | |
| Merz North America, INC. | $508.63 | 2019-2020 | |
| Astellas Pharma US INC | $272.83 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $163.19 | 2021-2023 | Slynd |
| Lilly USA, LLC | $145.40 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Avion Pharmaceuticals | $138.59 | 2019-2022 | |
| Corcept Therapeutics | $115.70 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $101.50 | 2020-2025 | |
| Exact Sciences Corporation | $75.22 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $74.01 | 2019-2025 | Evenity, Repatha, Otezla |
| Myovant Sciences INC. | $66.98 | 2021-2022 | |
| Novo Nordisk INC | $61.43 | 2023-2024 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $61.01 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $60.03 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $54.54 | 2024-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $46.55 | 2025 | Hetlioz, Fanapt |
| Recordati_rare_diseases_inc. | $43.85 | 2025 | Isturisa |
| Therapeuticsmd, INC. | $32.01 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.36 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.95 | 2025 | Rexulti |
| Lundbeck LLC | $22.70 | 2024 | Rexulti |
| Seqirus USA INC | $17.77 | 2024 | Flucelvax, Fluad |
| Scynexis, INC. | $17.23 | 2022 | |
| Mayne Pharma Commercial LLC | $16.38 | 2022 | |
| Lupin INC. | $15.66 | 2020 | |
| Dexcom, INC. | $15.36 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.73 | 2025 | Caplyta |
| Ardelyx, INC. | $14.67 | 2025 | Ibsrela |
| Organon LLC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Lahti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.